scholarly journals Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment – topical versus systemic

2012 ◽  
Vol 6 (5) ◽  
pp. 380-385 ◽  
Author(s):  
Alvaro Morales
Keyword(s):  
Premature Ejaculation ◽  
Therapeutic Strategies ◽  
On Demand

scholarly journals Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment – topical versus systemic

2012 ◽  
Vol 6 (5) ◽  
Author(s):  
Alvaro Morales
Keyword(s):  
Clinical Trials ◽  
Sexual Dysfunction ◽  
Sexual Satisfaction ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Premature Ejaculation ◽  
Therapeutic Strategies ◽  
Phase 3 ◽  
On Demand ◽  
Sexual Dissatisfaction ◽  
Ejaculatory Control

Premature ejaculation (PE) is a common sexual dysfunction affecting20% to 30% of men worldwide. Definitions of PE vary, but itis typically characterized by short intravaginal ejaculatory latencytime (IELT) with concomitant sexual dissatisfaction and distress.PE may be lifelong or acquired, but its etiology remains unclear.Treatment of PE typically involves pharmacotherapy, particularlywhen lifelong. Although there are numerous reports on the offlabeluse of selective serotonin reuptake inhibitors (SSRIs) andother compounds, only 2 treatments have been evaluated in randomizedcontrolled phase 3 clinical trials: PSD502 and dapoxetine(SSRI). Both significantly improved IELT and patient-reportedoutcome domains of ejaculatory control, sexual satisfaction, anddistress as measured by the index of premature ejaculation (IPE),compared with placebo. They constitute the focus of this review.Evidence demonstrated that PSD502, dapoxetine and other SSRIsall significantly improve the symptoms of PE. Systemic use of SSRIspresents risks associated with the known pharmacology of thisclass. PSD502 allows for topical on-demand treatment appliedapplied immediately before intercourse, and is not associated withsystemic adverse events.

ORIGINAL RESEARCH–EJACULATORY DISORDERS: Tramadol HCL has Promise in On-Demand Use to Treat Premature Ejaculation

2008 ◽  
Vol 5 (1) ◽  
pp. 188-193 ◽  
Author(s):  
Emad A. Salem ◽  
Steven K. Wilson ◽  
Nabil K. Bissada ◽  
John R. Delk ◽  
Wayne J. Hellstrom ◽  
...  
Keyword(s):  
Premature Ejaculation ◽  
Original Research ◽  
On Demand

Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta-analysis

Sexual Health ◽  
2019 ◽  
Vol 16 (4) ◽  
pp. 301
Author(s):  
Guo-Jiang Zhao ◽  
Qiang Guo ◽  
Yu-Feng Li ◽  
Yan-Gang Zhang
Keyword(s):  
Systematic Review ◽  
Premature Ejaculation ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Safety Data ◽  
Final Analysis ◽  
On Demand ◽  
Electronic Search ◽  
Dosing Regimens ◽  
Randomised Controlled

We conducted a systematic review and meta-analysis of published randomised controlled trials of dapoxetine for premature ejaculation. We systematically searched Embase, PubMed, Cochrane, Web of Knowledge, FDA.gov and Clinical Trials.gov for studies reporting dapoxetine in men with premature ejaculation. Efficacy endpoints included intravaginal ejaculatory latency times (IELT), personal distress related to ejaculation (PDRE) and treatment-emergent adverse events (TEAEs) was used to evaluate safety. Data were analysed using a random-effects model. Electronic search identified 276 papers. The final analysis included eight papers (n = 8422 subjects). Analysis of the pooled results indicated efficacy in both IELT (weighted mean difference (WMD) = 1.67, 95% confidence interval (CI) 1.45–1.89) and PDRE (relative risk = 1.26, 95% CI 1.18–1.35). Subgroup analysis indicated efficacy (i.e. increase in IELT) for 30- and 60-mg on-demand dapoxetine (WMD 1.38 (95% CI 1.01–1.75) and 1.62 (95% CI 1.40–1.84) respectively), as well as daily use of 60 mg dapoxetine (WMD 2.18, 95% CI 1.71–2.64). The safety profile was acceptable. Based on the different effects of magnitude of the three dosing regimens, we recommend a stepwise approach, starting with 30 mg on demand, then 60 mg on demand and finally 60 mg dapoxetine daily.

214 On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo-controlled clinical trial

2013 ◽  
Vol 12 (1) ◽  
pp. e214
Author(s):  
T.A. Gameel ◽  
A.M. Tawfik ◽  
M.G. Soliman ◽  
M.A. El-Bendary ◽  
M. Abo-Elenen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Local Anesthetics ◽  
Premature Ejaculation ◽  
Controlled Clinical Trial ◽  
On Demand
Sign in / Sign up

Export Citation Format

Share Document